- |||||||||| budesonide / Generic mfg., fluticasone / Generic mfg.
Journal: Current treatment options and long-term outcomes in patients with eosinophilic esophagitis. (Pubmed Central) - Jul 23, 2022
Further knowledge on eosinophilic esophagitis phenotypes is needed to ascertain who will benefit best from sustained therapy. Unanswered questions include an adequate definition for sustained remission, best strategies for maintenance drugs and diets, enhancement of treatment adherence, and proper monitoring for long-term surveillance.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
DUPILUMAB FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS: A MULTICENTER REAL-LIFE EXPERIENCE (Poster Stage 4) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1549;
Five patients received Dupilumab and 12 were treated with StF (9 with viscous budesonide and 3 with oral fluticasone). Our study confirms that Dupilumab may represent a valid therapeutic option in refractory EoE, improving clinical, endoscopic and especially histological activity of the disease.
- |||||||||| fluticasone / Generic mfg.
A CASE OF INHALED FLUTICASONE INDUCED ADRENAL INSUFFICIENCY () - Jul 16, 2022 - Abstract #ENDO2022ENDO_973;
While relatively safe, ICS can occasionally cause systemic side effects including adrenal suppression, bone loss, and cataract formation It should be kept in mind that the minimal effective dose has to be used with steroids and tapered off when no longer necessary. We describe the case of a 53 year old women with no significant co-morbidities other than asthma who developed adrenal insufficiency due to inhaled fluticasone that was proven by the high level of fluticasone metabolites in her urine.
- |||||||||| fluticasone / Generic mfg.
Review, Journal: A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination. (Pubmed Central) - Jul 15, 2022
Extensive study of several trials has established the superior efficacy of FP/FORM combination therapy over FP or FORM monotherapy, comparable efficacy with FP+FORM and non-inferiority to other ICS/LABA fixed-dose combinations. The safety profile of FP/FORM has also been found to be comparable with respect to its mono-components and their concurrent use, and also other ICS/LABA combinations such as formoterol/budesonide and fluticasone/salmeterol.
- |||||||||| budesonide / Generic mfg., fluticasone / Generic mfg.
High dose inhaled steroids: is there a risk of adrenal insufficiency? (Exchange 8-10, upper level) - Jul 10, 2022 - Abstract #BTSSummer2022BTS_Summer_40;
Patients on high dose steroid inhalers at risk of adrenal suppression should carry a steroid emergency card and advice on how to detect and prevent an adrenal crisis is crucial. Challenges still exist on how to manage these patients.
- |||||||||| fluticasone / Generic mfg.
Rationale and Design for Randomized, Double-Blind, EDS-Placebo–Controlled Trials of EDS-FLU in Chronic Rhinosinusitis (Ponce Foyer) - Jun 26, 2022 - Abstract #EAC2022EAC_1;
In the absence of a standardized drug development pathway for CRS, a panel of experts developed a novel study design for the exhalation delivery system with fluticasone (EDS-FLU) that meets the criteria set forth in prior FDA draft guidance and is feasible to conduct and generalizable to the CRS population... Thoughtful preparation, input from FDA, and applying an iterative process yielded a novel study design for testing CRS therapies.
- |||||||||| dexamethasone / Generic mfg., fluticasone / Generic mfg., paracetamol / Generic mfg.
Leser-Trélat sign: can it follow COVID-19 infection? () - Jun 23, 2022 - Abstract #BAD2022BAD_695;
Therefore, the appearance of the Leser-Trélat sign after COVID-19 infection was a possibility in this patient. The role of transforming growth factor-α and tumour necrosis-α in eruptive seborrhoeic keratoses, as well as in COVID-19 infection, can be a common area of interest to explore in the aetiology of this entity.
- |||||||||| fluticasone / Generic mfg.
Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma: The INCA Sun randomized clinical trial (8A - live streamed) - Jun 22, 2022 - Abstract #ERS2022ERS_4280;
P=N/A
At week 32, 11(11%) active and 21(21%) control patients required add-on biologic therapy OR 0.42, 95%CI [0.189-0.95], p=0.038), 3 of 19(16%) active and 11 of 25(44%) control patients who started on FP 500mcg/day were increased (OR 0.26; 95%CI [0.07–0.99], p=0.049), 26 of 83(31%) active and 13 of 73(18%) control patients were reduced to FP 500mcg/day, OR 2.11, 95%CI [1.01–4.74], p=0.047). Despite a lower treatment burden were no differences in asthma control, lung function, T2 inflammation, nor exacerbations between the two groups.
- |||||||||| Striverdi Respimat (olodaterol) / Boehringer Ingelheim
Assessment of inhaled medications using an in vitro human alveolar microphysiological system. (TP-9 in thematic poster area) - Jun 22, 2022 - Abstract #ERS2022ERS_3841;
This is consistent with clinical data that shows higher retention, and therefore longer lasting effects, of these drugs in lung tissue. The alveolar MPS was predictive of compound dynamics in the lung and will be used to analyse pharmacology and toxicity of inhaled compounds in future studies.
- |||||||||| fluticasone / Generic mfg.
Effects of inhaled corticoids on chronic bronchial infection by Pseudomonas aeruginosa in COPD patients (8F) - Jun 22, 2022 - Abstract #ERS2022ERS_782;
Aim: to investigate the expression of TLR2 and c-Jun in broncheoalveolar lavage (BAL) macrophages from COPD patients, infected with Pseudomonas aeruginosa (PA) and treated ex vivo with budesonide (B) or fluticasone (F)...Conclusions We observed that the TLR2 and c-Jun response to PA is blunted in BAL macrophages from COPD patients and, although appearing when co-treated with B or F, it remains inhibited in the COPD patients that are under ICS treatment. Although preliminary, these data suggest an effect of ICS in COPD patients thus inhibiting the inflammatory response though TLR2 and c-Jun, which potentially confers them a higher risk of pneumonia infection.
- |||||||||| fluticasone / Generic mfg.
Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients (8F) - Jun 22, 2022 - Abstract #ERS2022ERS_778;
A historical, observational study using patients ≥40 years, with ≥1 year of continuous medical data and who were commencing a fixed dose of extrafine beclometasone (ef-B), fine particle fluticasone (fp-F) or long-acting bronchodilators (LABD) was conducted... Reduced pneumonia risk in COPD patients commencing ef-B is an important observation, particularly for individuals at high risk due to demographic and clinical factors.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron, Nucala (mepolizumab) / GSK, Xolair (omalizumab) / Roche, Novartis
Journal: Do Federal Regulations Affect Gender, Racial, and Ethnic Disparities in Chronic Rhinosinusitis Research? (Pubmed Central) - Jun 8, 2022
The racial, ethnic, and gender demographics of patients enrolled in CRSwNP clinical trials registered with the NIH differ significantly from the demographics of the US population, despite federal guidelines advising demographically representative participation. Proactive efforts to enroll participants that better represent anticipated treatment populations should be emphasized by researchers, institutions, and editorial boards.
- |||||||||| fluticasone / Generic mfg.
Review, Journal: Fluticasone/Formoterol compared withother ICS/LABAs in asthma: A systematic review. (Pubmed Central) - Jun 4, 2022
The present systematic review was undertaken to compare the clinical efficacy and safety of formoterol fluticasone (FF) to other ICS/LABA combinations in asthmatics...Only trials comparing the efficacy and safety of FF in comparision with Salmeterol/fluticasone (SF) or Budesonide/Formoterol (BF) were selected...Pneumonia risk was least with FF usage.ConclusionFF provides faster onset of action, numerically superior improvement in lung function and comparable asthma control than other ICS-LABA formulations. FF has better safety evidenced by lower occurrence of pneumonia.
- |||||||||| fluticasone / Generic mfg.
Journal, Real-world evidence: Tiotropium Add-On and Treatable Traits in Asthma-COPD Overlap: A Real-World Pilot Study. (Pubmed Central) - Jun 4, 2022
A 12-week open-label cross-over pilot study was conducted in patients with ACO to investigate the effect of tiotropium bromide (TIO) 5 µg/day add-on therapy to fluticasone propionate/formoterol fumarate (FP/FM) 500/20 µg/day compared with FP/FM 500/20 µg/day alone...FEV values after the TIO add-on therapy FP/FM period were significantly higher than those after the run-in period (p < 0.01). TIO add-on therapy to FP/FM in patients with ACO, considered difficult to treat because of the presence of both asthma and COPD, resulted in improvements in lung function parameters in this real-world pilot study, indicating the potential value of TIO add-on therapy as a "treatable traits" option for standard treatment for ACO.
- |||||||||| Journal: Drug treatment strategies for eosinophilic esophagitis in adults. (Pubmed Central) - May 25, 2022
Finally, the authors briefly look at the value of monoclonal antibodies targeting IL-5RA, IL-13, IL-4 or Siglec8, and oral S1PR agonists to the treatment of EoE...Investigational therapies that target several Th2-associated diseases seem useful in EoE. Comparative effectiveness and cost-utility analyses will help to position them in a complex therapeutic scenario.
- |||||||||| ampicillin / Generic mfg., azithromycin / Generic mfg., fluticasone / Generic mfg.
ONCE UPON A TIME, PNEUMONIA... SARS-COV-2: GUILTY OR INNOCENT? () - May 19, 2022 - Abstract #ESPID2022ESPID_1197;
Empirical antibiotic therapy was started with ampicillin and azithromycin, with no improvement in pain...He underwent a short course of oral corticosteroid therapy and was discharged home with daily inhaled fluticasone...Learning Points/ This case demonstrates the low specificity of the symptoms caused by SARS-CoV-2 in Pediatrics, as well as of the CT findings, and shows the pulmonary involvement after asymptomatic infection. The authors thus intend to draw attention to the need to share knowledge for the early recognition of this challenging disease.
- |||||||||| fluticasone / Generic mfg.
Journal: Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression. (Pubmed Central) - May 15, 2022
This builds on previous research that identified a SNP in PDGFD (rs591118) as an independent risk factor for adrenal suppression in adults and children with obstructive airway disease treated with inhaled corticosteroids. First in vitro experiments to support a link between the PDGF and cortisol production pathways, supporting the hypothesis that PDGFD variants can affect an individual's sensitivity to corticosteroid-induced adrenal suppression.
- |||||||||| thapsigargin / University of Nottingham, Pirbright Institute, Mifeprex (mifepristone) / Danco Laboratories
A CHEMOTRANSCRIPTOMIC SCREENING IDENTIFIES THE REVERSAL OF GLUCOCORTICOID RESISTANCE IN NOTCH1 MUTATED T-ALL () - May 13, 2022 - Abstract #EHA2022EHA_588;
Consequently, the association of SI plus GC displayed a synergistic effect in multiple preclinical models, including steroid-resistant cell lines, primary leukemia cells, and PDX models. Conclusion These findings suggest that SERCA-Ca 2+ modulation mediates GC and steroid signaling and that innovative SI can pharmacologically modulate glucocorticoid resistance in T-ALL.
- |||||||||| solithromycin (CEM-101) / Melinta Therap, Fujifilm Holdings, Sovaldi (sofosbuvir) / Gilead
Journal: Biocatalytic Asymmetric Construction of Secondary and Tertiary Fluorides from β-Fluoro-α-ketoacids. (Pubmed Central) - May 12, 2022
The reactivity of HpcH towards these fluoro-donors grants access to enantiopure secondary or tertiary fluorides. In addition to representing the first synthesis of tertiary fluorides via biocatalytic carboligation, the afforded products could improve the diversity of fluorinated building blocks and enable the synthesis of fluorinated drug analogs.
- |||||||||| Onon dry syrup (pranlukast) / Ono Pharma
Journal: The Effects of Combined Therapeutic Protocol on Allergic Rhinitis Symptoms and Molecular Determinants. (Pubmed Central) - May 8, 2022
Allergic symptoms (nasal rubbing and sneezing), serum Igs (IgG1, total and OVA-specific IgE), eicosanoids (LTB4 and LTC4), histamine, TSLP, and IL-4 as well as gene expressions of MUC5a, Caspase-1, NLR3, HRH1, and CysLT1R were reduced in the animals receiving each of the therapeutic regimens; however, more pronounced effects were seen in the group treated with the triple combined protocol (loratadine + fluticasone + pranlukast). The combination of the loratadine, fluticasone, and pranlukast can effectively control the symptoms of AR probably via modulating several related mechanisms at early and late phases of allergic responses.
- |||||||||| fluticasone / Generic mfg.
Journal: An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone. (Pubmed Central) - May 3, 2022
The majority (n = 480, 81.9%) of the patients received fluticasone (Flovent)® as the standard of care ICS treatment for controlling asthma, and a small proportion (n = 106, 18.1%) were treated with a combination of LABA and ICS...Moderate to severe exacerbations were significantly higher in the ICS group compared to the combination group (95.6% versus 84.5%, respectively, p = 0.0005). The current results confirm the substantial efficacy of the LABA/ICS combination therapy in reducing the incidence and severity of asthma exacerbations in pediatric patients, compared to ICS alone.
- |||||||||| vilanterol (GW642444H) / GSK, Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Enrollment open, Trial completion date, Trial primary completion date, Head-to-Head: Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults (clinicaltrials.gov) - May 2, 2022
P2/3, N=130, Recruiting,
The current results confirm the substantial efficacy of the LABA/ICS combination therapy in reducing the incidence and severity of asthma exacerbations in pediatric patients, compared to ICS alone. Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
- |||||||||| fluticasone / Generic mfg.
PRE-TREATMENT DIFFERENTIAL CORRELATION OF GENE EXPRESSION DOES NOT PREDICT SUBSEQUENT RESPONSE TO TOPICAL STEROID TREATMENT IN EOSINOPHILIC ESOPHAGITIS (Poster Hall - San Diego Convention Center) - Apr 25, 2022 - Abstract #DDW2022DDW_1250;
Methods : We performed a secondary analysis of data and specimens collected during a randomized trial comparing budesonide slurry and fluticasone metered dose inhaler for treatment of newly diagnosed EoE...Conclusion s: A 22 gene panel that we previously identified to predict treatment non-response to topical steroids in EoE patients using differential correlation of baseline (pre-treatment) gene expression was not able to be validated in an independent population. Alternative Methods to predict steroid response should be explored.
|
